Study to Evaluate the Safety and Efficacy of IPN59011 in... | NCT04736745

ID	Type	Description	Link
2019-003268-33	EudraCT Number

Status Module

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Dose escalation	Experimental	One single injection of study medication (IPN59011 or Placebo) will be injected locally. IPN59011 is injected in a dose-escalation manner. In total for this stage at least 40 subjects.	Biological: IPN59011 Drug: Placebo
Dose ranging	Experimental	Up to two IPN59011dose(s) groups will be included in parallel groups versus Azzalure group and placebo group. One single injection of study medication will be injected locally into several sites. In total for this stage at least 70 subjects.	Biological: IPN59011 Biological: Azzalure Drug: Placebo
Additional dose ranging	Experimental	Dose-ranging for three additional placebo-controlled parallel groups. One single injection of study medication will be injected locally into several sites, concomitantly and non-concomitantly. In total for this stage at least 110 subjects.	Biological: IPN59011 Drug: Placebo
Total dose for Upper Facial Lines	Experimental	One single injection of study medication will be injected locally into Upper Facial Lines. In total for this stage approximately 48 subjects.	Biological: IPN59011 Drug: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
IPN59011	Biological	Powder and solvent for solution for injection	Additional dose ranging Dose escalation Dose ranging Total dose for Upper Facial Lines

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Incidence of the Treatment-Emergent Adverse Events (TEAEs) at each dose for dose escalation		from baseline until the end of study (9 months)
Incidence of Serious Adverse Events (SAEs) at each dose for dose escalation		from baseline until the end of study (9 months)
Incidence of clinically significant Adverse Events (AEs) at each dose for dose escalation		from baseline until the end of study (9 months)
Incidence of AEs (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs) for dose escalation		from baseline until the end of study (9 months)
Presence of botulinum neurotoxin serotype A (BoNT-A) antibodies and IPN59011 antibodies and titres (binding and neutralizing)		from baseline until the end of study (9 months)
Response to treatment measured by the composite response of 2-grade improvement on investigator's live assessment (ILA) at maximum contraction.	ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs at maximum frown and at rest where 0 is "no lines are noticeable" and 3 is "lines are extremely pronounced".	Day 29
Response to treatment measured by the composite response of 2-grade improvement on subject's self-assessment (SSA) at maximum contraction.	SSA: a validated 4-point categorical scale to assess the appearance of their Glabellar Lines (GLs) at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles".	Day 29

Secondary Outcomes

Measure	Description	Time Frame
Response to treatment as measured by the reduction of ≥2 grades on the ILA at maximum contraction		From the baseline to the end of the study (9 months)
Response to treatment as achieved by a score of "none" or "mild" as measured by the ILA at maximum contraction

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Provision of written informed consent prior to any study related procedures.
Female and male subjects between 18 and 65 years of age, inclusive (for dose escalation females only)
Moderate or severe (Grade 2 or 3) GL at maximum contraction at Baseline, as assessed by the ILA using a validated 4-point photographic scale.
Moderate or severe (Grade 2 or 3) GL at maximum contraction at Baseline, as assessed by the SSA using a validated 4-point categorical scale.
Moderate or severe (Grade 2 or 3) Forehead Lines (FHL) at maximum contraction and moderate to severe GL at maximum contraction at Baseline or moderate to severe (Grade 2 or 3) Lateral Canthal Lines (LCL) at maximum contraction (Stage as assessed by the ILA using a validated 4-point photographic scale).
Moderate or severe (Grade 2 or 3) FHL at maximum contraction and moderate to severe GL at maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL at maximum contraction (Stage as assessed by the ILA using a validated 4-point photographic scale).
Moderate or severe (Grade 2 or 3) FHL at maximum contraction and moderate to severe GL maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL at maximum contraction, as assessed by the by the SSA using a validated 4-point categorical scale.
Moderate or severe (Grade 2 or 3) FHL at maximum contraction and moderate to severe GL maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL at maximum contraction, as assessed by the by the SSA using a validated 4-point categorical scale.
Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines at Baseline, as assessed by the subject's level of satisfaction.
A negative pregnancy test (for females of childbearing potential only). Non-childbearing potential is defined as postmenopausal for at least 1 year; surgical sterilisation at least 3 months before entering the study; or hysterectomy.
Subject has both the time and the ability to complete the study and comply with study instructions.

Exclusion Criteria:

Previous treatment with any Botox (BTX) serotype (for dose escalation at least) or any recent treatment (within the past 6 months prior to Baseline for the rest of the study) with any BTX serotype.
Any prior treatment with permanent fillers in the upper face including the GL, FHL and LCL area.
Any prior treatment with long lasting dermal fillers in the upper face including the GL area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photo rejuvenation or skin/vascular laser intervention within the 12 months prior to Baseline.
Any planned facial cosmetic surgery during the study.
A history of eyelid blepharoplasty or brow lift within the past 5 years.
An inability to substantially reduce GL by physically spreading them apart or lack of capacity to frown.
An active infection or other skin problems in the upper face including the GL, FHL and LCL area (e.g. acute acne lesions or ulcers).
Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study treatment, including medications affecting bleeding disorders (e.g. antiplatelet agents and/or anticoagulants given for treatment or prevention of cardiovascular/cerebrovascular diseases).
Pregnant women, nursing women, premenopausal women or women of childbearing potential (i.e. not surgically sterile or 1 year postmenopausal) not willing to practice a highly effective form of contraception method at the beginning of the study, for the duration of the study and for a minimum of 12 weeks following last administration of study treatment. Highly effective methods of contraception are defined as methods of birth control which result in a low failure rate (less than 1% per year) when used consistently and correctly such as implants, injectables, combined oral contraceptives, intrauterine devices, or vasectomised partner.
Male subjects who are not vasectomised and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation for a minimum of 12 weeks following initial double-blind administration of the treatment.
Positive for hepatitis B antigen, or hepatitis C virus antibody, or for human immunodeficiency virus (HIV) or a diagnosis of acquired immunodeficiency syndrome.
A history of drug or alcohol abuse.
Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the half life is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study.
Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the subject's participation in the study.
Use of medications that affect neuromuscular transmission, such as curare-like nondepolarising agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics, within the past 30 days prior to Baseline.
A history of facial nerve palsy.
Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
Known allergy or hypersensitivity to BTX, or any excipients of IPN59011 or Azzalure, or allergy to cow's milk protein.
Any known medical condition that may put the subject at increased risk in regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.)
The presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgment of the investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
Any uncontrolled systemic disease or other significant medical condition considered as an exclusion criteria.